Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy

Griffin, J.L.; Sang, E.; Evens, T.; Davies, K.; Clarke, K.
October 2002
FEBS Letters;Oct2002, Vol. 530 Issue 1-3, p109
Academic Journal
Metabolic profiles from 1H nuclear magnetic resonance spectroscopy have been used to describe both one and two protein systems in four mouse models related to Duchenne muscular dystrophy using the pattern recognition technique partial least squares. Robust statistical models were built for extracts and intact cardiac tissue, distinguishing mice according to expression of dystrophin. Using metabolic profiles of diaphragm, models were built describing dystrophin and utrophin, a dystrophin related protein, expression. Increased utrophin expression counteracted some of the deficits associated with dystrophic tissue. This suggests the method may be ideal for following treatment regimes such as gene therapy.


Related Articles

  • Screening of dystrophin gene deletions in Egyptian patients with DMD/BMD muscular dystrophies. Effat, Laila K.; El-Harouni, Ashraf A.; Amr, Khalda S.; El-Minisi, Tarik I.; Abdel Meguid, Nagwa; El-Awady, Mostafa // Disease Markers;2000, Vol. 16 Issue 3/4, p125 

    Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are allelic disorders caused by mutations within the dystrophin gene. Our study has identified 100 Egyptian families collected from the Human Genetics Clinic, National Research Center, Cairo. All cases were subjected to...

  • Dystrophin, Utrophin, and Muscular Dystrophy. Karpati, George; Holland, Paul // New England Journal of Medicine;3/2/95, Vol. 332 Issue 9, p612 

    A letter to the editor is presented in response to the article "Absence of Dystrophin and Utrophin in a Boy with Severe Muscular Dystrophy," by M-P Chevron, B. Echenne, and J. Damaille in the October 27, 1994 issue.

  • Dystrophin, Utrophin, and Muscular Dystrophy. Chevron, Marie-Pierre // New England Journal of Medicine;3/2/95, Vol. 332 Issue 9, p612 

    A response by Marie-Pierre Chevron in response to his article on a patient with Duchenne's muscular dystrophy and an absence of dystrophin is presented.

  • Gene Therapy for Muscular Dystrophies: Current Status and Future Prospects. Takeda, S.; Miyagoe-Suzuki, Y. // BioDrugs;2001, Vol. 15 Issue 10, p635 

    Since the identification in 1987 of the gene for Duchenne muscular dystrophy (DMD), research on the molecular pathogenesis of muscular dystrophy has progressed extensively. In particular, discovery of the DMD gene product, dystrophin, led to the identification of dystrophin-associated proteins...

  • Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. Jahnke, Vanessa E.; Van Der Meulen, Jack H.; Johnston, Helen K.; Ghimbovschi, Svetlana; Partridge, Terrence; Hoffman, Eric P.; Nagaraju, Kanneboyina // Skeletal Muscle;2012, Vol. 2 Issue 1, p16 

    Background: Duchenne muscular dystrophy is a genetic disease involving a severe muscle wasting that is characterized by cycles of muscle degeneration/regeneration and culminates in early death in affected boys. Mitochondria are presumed to be involved in the regulation of myoblast...

  • Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice. Yang, L; Lochmuller, H; Luo, J; Massie, B; Nalbantoglu, J; Karpati, G; Petrof, B J // Gene Therapy;Mar1998, Vol. 5 Issue 3, p369 

    Duchenne muscular dystrophy (DMD) and murine X-linked muscular dystrophy (mdx) are both due to absence of the subsarcolemmal protein dystrophin. Recombinant adenovirus vectors (AdV) are considered a promising means for delivering a functional dystrophin gene to muscle. However, the usefulness of...

  • In vivo correction of muscular dystrophy. Jamison, Judy // Nature Biotechnology;Jun2000, Vol. 18 Issue 6, p586 

    Discusses that gene therapy for Duchenne muscular dystrophy (DMD) has failed to produce long-term stable expression of the dystrophin gene product. Reasons for the failure of gene therapy for DMD; Use of chimeric oligonucleotides to repair sickle cell mutations.

  • A novel miniDys_eGFP fusion gene for developing cell_based therapies of Duchenne muscular dystrophy  // Molecular Therapy;May2004 Supplement 1, Vol. 9, p93 

    An abstract of the article "A Novel MiniDys-eGFP Fusion Gene for Developing Cell-Based Therapies of Duchenne Muscular Dystrophy," by Sheng Li, En Kimura, Leonard Meuse, Xin Ye, Brent Fall, Steven D. Hauschka, John Faulkner and Jeffrey S. Chamberlain is presented.

  • Delivery of Igf_I and dystrophin to dystrophic mdx muscle  // Molecular Therapy;May2004 Supplement 1, Vol. 9, p93 

    An abstract of the article "Delivery of Igf-I and Dystrophin to Dystrophic mdx Muscle," by Simone Abmayr, Paul Gregorevic, James M. Allen, Shanna M. Sawatzki and Jeffrey S. Chamberlain is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics